11 October 2022>: Original Paper
Reduced Risk of Chronic Graft-Versus-Host Disease (cGVHD) by Rabbit Anti-Thymocyte Globulin (ATG) in Patients Undergoing Matched Sibling Donor Transplantation in Hematological Malignancies
Shu Fang 12ABCDEF* , Nan Wang 23ABCF* , Lili Wang 2ABCD* , Jishan Du 23BCF , Jingjing Yang 23BCF , Yanan Wen 23BCF , Yan Wei 23BCF , Kun Qian 12BCD , Hao Wang 23ABF , Yifan Jiao 23BCF , Chunji Gao 12ACEG* , Liping Dou 2ABDEG*DOI: 10.12659/AOT.937356
Ann Transplant 2022; 27:e937356
Table 5 Univariate analysis of risk factors for moderate to severe cGVHD and CIR in all patients.
Moderate to severe cGVHD | CIR | |||||
---|---|---|---|---|---|---|
HR | 95% CI | p | HR | 95% CI | p | |
ATG vs non-ATG | 0.301 | 0.099–0.918 | 0.035 | 2.158 | 1.051–4.430 | 0.036 |
Recipient age (≥ median vs < median) | 0.407 | 0.152–1.084 | 0.072 | 1.405 | 0.687–2.875 | 0.352 |
Donor age (≥ median vs < median) | 0.591 | 0.229–1.526 | 0.278 | 1.633 | 0. 798–3.343 | 0.180 |
Donor-recipient gender match | ||||||
Female to male vs others | 1.438 | 0.556–3.720 | 0.454 | 1.125 | 0.542–2.334 | 0.752 |
Donor-recipient ABO match | ||||||
Mismatch vs match | 0.907 | 0.340–2.420 | 0.846 | 1.405 | 0.699–2.827 | 0.340 |
Diagnosis (ALL vs others) | 0.765 | 0.250–2.343 | 0.639 | 1.701 | 0.830–3.489 | 0.147 |
Time interval between diagnosis and HSCT | ||||||
≥6 m vs | 0.737 | 0.291–1.872 | 0.521 | 0.577 | 0.282–1.181 | 0.132 |
Cytogenetic risk | ||||||
High vs favorable/intermediate | 0.434 | 0.125–1.499 | 0.187 | 1.147 | 0.543–2.424 | 0.719 |
Disease status at HSCT | ||||||
Untreated/refractory/relapsed vs CR | 1.300 | 0.428–3.953 | 0.644 | 1.170 | 0.506–2.706 | 0.714 |
Disease risk index | ||||||
High/very high vs low/intermediate | 0.418 | 0.121–1.443 | 0.168 | 1.610 | 0.794–3.264 | 0.187 |
MNC (≥ median vs < median) | 0.789 | 0.311–2.001 | 0.618 | 1.159 | 0.579–2.322 | 0.677 |
CD34 (≥ median vs < median) | 0.829 | 0.326–2.107 | 0.694 | 1.548 | 0.763–3.141 | 0.226 |
aGVHD (Grades 2–4 vs grades 0–1) | 0.700 | 0.249–1.968 | 0.499 | 2.158 | 1.051–4.430 | 0.036 |
ATG – anti-thymocyte globulin; aGVHD – acute graft-versus-host disease; cGVHD – chronic graft-versus-host disease; CIR – cumulative incidence of relapse; HSCT – hematopoietic stem cell transplantation; ALL – acute lymphoblastic leukemia; CR – complete remission; MNCs – mononuclear cells. |